Drag a card by its title · ⚙ to size, swap or remove

The company

Roivant Sciences Ltd. - Common Shares

ROIV · Nasdaq

Health CareBiotechnologyIn trend

ROIV stood above a rising 150-day average in 52 of the last 52 weekly readings, every one of them. It is 2.7% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: In trend
Weeks in an uptrend: 52 in a row
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $1.4B
Officials’ trades on record: 4
Institutions holding: 471 (+53)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 52 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

4 disclosed lines: House 4, Senate 0, executive 0; 1 people.

Who	Did	Amount	Traded
Lisa C. McClain House: U.S. House ClerkMI09	soldspouse	$1k–$15k	31 Oct 2025filed 21 Nov 2025
Lisa C. McClain House: U.S. House ClerkMI09	soldspouse	$1k–$15k	30 Oct 2025filed 21 Nov 2025
Lisa C. McClain House: U.S. House ClerkMI09	boughtspouse	$1k–$15k	30 Oct 2025filed 21 Nov 2025
Lisa C. McClain House: U.S. House ClerkMI09	boughtspouse	$1k–$15k	17 Jun 2025filed 13 Aug 2025

Insiders

Buy orders, 12 months0

Sale orders, 12 months73

Buyers · sellers0 · 12

Who	Did	Shares	Traded
Epperly Melissa B.Director	sold	16,850at $36.08	1 Oct 2026filed 5 Oct 2026
Epperly Melissa B.Director	sold	900at $36.57	1 Oct 2026filed 5 Oct 2026
Eric VenkerPresident & Immunovant CEO	sold	200,000at $36.62	30 Sep 2026filed 2 Oct 2026
Meghan FitzgeraldDirector	sold	4,712at $39.68	15 Sep 2026filed 17 Sep 2026
Meghan FitzgeraldDirector	sold	400at $40.45	15 Sep 2026filed 17 Sep 2026
Epperly Melissa B.Director	sold	4,338at $39.65	15 Sep 2026filed 17 Sep 2026
Epperly Melissa B.Director	sold	600at $40.38	15 Sep 2026filed 17 Sep 2026
Meghan FitzgeraldDirector	sold	20,000at $39.90	8 Sep 2026filed 10 Sep 2026
Eric VenkerPresident & Immunovant CEO	sold	166,182at $35.63	28 Aug 2026filed 1 Sep 2026
Eric VenkerPresident & Immunovant CEO	sold	33,818at $36.44	28 Aug 2026filed 1 Sep 2026
Mayukh SukhatmePresident & CIO	sold	144,756at $36.48	21 Aug 2026filed 21 Aug 2026
Mayukh SukhatmePresident & CIO	sold	17,519at $37.30	20 Aug 2026filed 21 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders471+53 on the quarter

New · exited95 · 44

Reported value$19.5B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
FMR LLCadded · filed 13 Aug 2026	81,020,390$2.9B	+3,039,137+3.9%
BlackRock, Inc.added · filed 7 Aug 2026	48,236,091$1.7B	+3,981,831+9.0%
MORGAN STANLEYreduced · filed 13 Aug 2026	42,592,905$1.5B	-9,235,420−17.8%
QVT Financial LPreduced · filed 14 Aug 2026	23,723,074$839.6M	-1,438,163−5.7%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	22,123,198$782.9M	+1,442,626+7.0%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026	21,641,339$765.9M	+1,802,641+9.1%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 2026	18,556,458$656.7M	+7,444,867+67.0%
STATE STREET CORPadded · filed 7 Aug 2026	17,795,975$629.8M	+1,609,362+9.9%
UBS Group AGreduced · filed 13 Aug 2026	17,466,641$618.1M	-5,152,831−22.8%
FARALLON CAPITAL MANAGEMENT, L.L.C.added · filed 14 Aug 2026	14,309,000$506.4M	+4,634,000+47.9%